ArticleBritish journal of clinical pharmacology2011
When to publish measures of disproportionality derived from spontaneous reporting databases?
Article in British journal of clinical pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis.British journal of clinical pharmacology · 2014Pooled it
- Article
- Charting and Sidestepping the Pitfalls of Disproportionality Analysis.Drug safety · 2026Review
- FDA Adverse Event Reporting System (FAERS) Essentials: A Guide to Understanding, Applying, and Interpreting Adverse Event Data Reported to FAERS.Clinical pharmacology and therapeutics · 2025Article
- A disproportionality analysis of nervous system adverse events associated with disease-modifying therapies in multiple sclerosis: insights from the FDA adverse event reporting system (FAERS).Journal of neurology · 2025Article
- Post-marketing safety profile of ganirelix in women: a 20-year pharmacovigilance analysis of global adverse drug event databases (2004-2024).BMC pharmacology & toxicology · 2025Article
- Disproportionality Analysis and Causal Inference in Drug Safety.Pharmaceutical medicine · 2025Review
- Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases.Frontiers in pharmacology · 2025Article
- Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system.Frontiers in pharmacology · 2025Article
- Peer Review in Pharmacovigilance: Lens on Disproportionality Analysis.Drug safety · 2024Article
- Article
- Not Just Another Reporting Guideline? Here's Why READUS-PV is a Major Step Forward.Drug safety · 2024Article
- The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline.Frontiers in pharmacology · 2024Article
- Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems.Frontiers in drug safety and regulation · 2023Review
- Neuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: A real-world analysis of the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).The World Allergy Organization journal · 2021Article
- Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance.Targeted oncology · 2020Review
- Gabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system.Drug and alcohol dependence · 2020Article
- Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System.SAGE open medicine · 2019Article
- Sources of Safety Data and Statistical Strategies for Design and Analysis: Postmarket Surveillance.Therapeutic innovation & regulatory science · 2018Review
- Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?Clinical drug investigation · 2017Review
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.